Promising antimycotics for the treatment of invasive infections [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2023 This paper provides a review of the largest studies (over the period of 2018 to 2023) of promising novel antimycotics and their possible role in the treatment of invasive mycoses, including infections caused by resistant Candida and Aspergillus isolates.
Ortenberg E.А.
doaj +1 more source
Efficacy and safety of oral ibrexafungerp in Chinese patients with vulvovaginal candidiasis: a phase III, randomized, double-blind study. [PDF]
InfectionWang X +34 more
europepmc +3 more sources
Profil ADME dari Entitas Molekul Baru yang Disetujui oleh FDA Tahun 2021: Suatu Kajian In Silico [PDF]
, 2022 Aspek farmakokinetik dan farmakodinamik yang diwakili oleh sifat adsorpsi, distribusi, metabolisme, ekskresi (ADME) merupakan syarat penting suatu obat dapat menuju targetnya.
Arief, Ihsanul, Hairunnisa, Hairunnisa
core +1 more source
The Latest FDA-Approved Pharmaceuticals Containing Fragments of Tailor-Made Amino Acids and Fluorine [PDF]
, 2022 Nowadays, the selective introduction of fluorine into bioactive compounds is a mature strategy in the design of drugs allowing to increase efficiency, biological half-life and bio-absorption. On the other hand, amino acids (AAs) represent one of the most
Butler, Greg +5 more
core +1 more source
Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix [PDF]
Pharmacotherapy: The Journal of Human Pharmacology and Drug TherapyAbstractManagement of invasive fungal infections is challenging with growing antifungal resistance. Broad antifungal use has resulted in greater intrinsic and acquired resistance among Candida spp. It is important for clinicians to recognize the relationship between host susceptibility, site of infection, Candida resistance profiles, specific drug ...
Benjamin August, Pramodini Kale-Pradhan
openalex +3 more sources
Fungal cell wall : An underexploited target for antifungal therapies [PDF]
, 2021 Funding: The authors would like to acknowledge support from the University of Aberdeen and Abia State University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Peer ...
Ibe, Chibuike, Munro, Carol
core +1 more source
Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis [PDF]
Clinical Infectious Diseases, 2021 Abstract Background Vulvovaginal candidiasis affects approximately 75% of women in their lifetime. Approved treatment options are limited to oral or topical azoles. Ibrexafungerp, a novel, first-in-class oral triterpenoid glucan synthase inhibitor, has demonstrated broad fungicidal Candida activity ...
Nyirjesy, Paul +5 more
openaire +2 more sources
1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model [PDF]
Open Forum Infectious Diseases, 2020 Abstract Background Pneumocystis pneumonia (PCP) is an opportunistic fungal infection that affects immunocompromised patients. Ibrexafungerp (IBX) is an oral and intravenous antifungal from a novel class of glucan synthase inhibitors, triterpenoids, and has shown activity against Candida, Aspergillus,
Katyna Borroto–Esoda +4 more
openalex +2 more sources
Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains. [PDF]
Antimicrob Agents ChemotherCeballos-Garzon A +5 more
europepmc +2 more sources
Journal of Fungi, 2023 The epidemiology of invasive fungal infections (IFIs) is currently changing, driven by aggressive immunosuppressive therapy, leading to an expanded spectrum of patients at risk of IFIs.
Roya Vahedi-Shahandashti +3 more
doaj +1 more source